重组小鼠趋化因子配体5，His-标签（无动物源）（CCL5）

重组小鼠趋化因子配体5，His-标签（无动物源）

PRP1190 | Mouse CXCL5 Protein, His tag (Animal-Free)

核心参数：

• ▸ 活性验证：ED₅₀＜100ng/mL（CXCR2-BaF3细胞趋化实验）
• ▸ 超高纯度：＞98%（SDS-PAGE验证）
• ▸ 超低内毒素：＜0.1 EU/µg（LAL法检测）
• ▸ 分子特性：9 kDa单体蛋白，大肠杆菌表达系统

产品优势

采用无动物源生产工艺，有效规避外源病毒风险，冻干粉形态确保长期稳定性，复溶后保持＞98%单体率，适用于细胞迁移、血管生成等精细研究。

规格与定价

• ▶ 5 µg 现货 ¥588
• ▶ 20 µg 现货 ¥1,498
• ▶ 100 µg 定制 ¥3,589
• ▶ 1 mg 批量 询价

保存指南：

冻干态-20°C保存12个月，复溶后4°C稳定7天，含稳定剂的稀释液-80°C可保存6个月（避免反复冻融）。

关键应用

炎症机制研究｜血管生成实验｜趋化因子受体CXCR2功能验证｜肿瘤微环境模拟

检测指标：

ENA-78/AMCF-II/Cxcl6等13种异构体精准识别，UniProt ID：P50228

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

Recombinant Mouse Chemokine (C-X-C motif) Ligand 5, His-Tag (Animal-Free)

PRP1190 | Mouse CXCL5 Protein, His tag (Animal-Free)

Key Parameters:

• ▸ Activity Validation: ED₅₀ < 100 ng/mL (CXCR2-BaF3 Cell Chemotaxis Assay)
• ▸ High Purity: > 98% (SDS-PAGE Verification)
• ▸ Ultra-Low Endotoxin: < 0.1 EU/µg (LAL Assay)
• ▸ Molecular Characteristics: 9 kDa Monomeric Protein, E. coli Expression System

Product Advantages

Manufactured using animal-free production processes to effectively avoid exogenous virus risks. Lyophilized powder ensures long-term stability, maintaining > 98% monomer rate after reconstitution. Suitable for detailed studies such as cell migration and angiogenesis.

Specifications & Pricing

• ▶ 5 µg In Stock ¥588
• ▶ 20 µg In Stock ¥1,498
• ▶ 100 µg Custom Order ¥3,589
• ▶ 1 mg Bulk Inquiry

Storage Guidelines:

Lyophilized state: Store at -20°C for 12 months. After reconstitution, stable at 4°C for 7 days. Diluent with stabilizer can be stored at -80°C for 6 months (avoid repeated freeze-thaw cycles).

Key Applications

Inflammation Mechanism Research | Angiogenesis Experiments | Chemokine Receptor CXCR2 Functional Validation | Tumor Microenvironment Simulation

Detection Indicators:

Accurate identification of 13 isoforms including ENA-78/AMCF-II/Cxcl6, UniProt ID: P50228

Note: The above information may change due to product optimization and upgrades. For specific information, please consult Abbkine Company.